Melita Jung

Corporate Officer/Principal bei TERNS PHARMACEUTICALS, INC.

Vermögen: - $ am 30.04.2024

47 Jahre

Health Technology

Consumer Services

Commercial Services

Aktive Positionen von Melita Jung

Unternehmen	Position	Beginn	Ende
TERNS PHARMACEUTICALS, INC.	Corporate Officer/Principal	22.04.2024	-

Unternehmen	Position	Beginn	Ende
SANGAMO THERAPEUTICS, INC.	Corporate Officer/Principal	01.07.2017	01.01.2021
ADAMAS PHARMACEUTICALS, INC.	Corporate Officer/Principal	01.07.2014	01.06.2017
Ascendancy Healthcare, Inc. Ascendancy Healthcare, Inc. Pharmaceuticals: MajorHealth Technology Ascendancy Healthcare, Inc. engages in the commercialization of pharmaceutical productS. It enables product entry by providing clinical, regulatory and commercial expertise and oversight along with funding. The company was founded by Arthur Joseph Higgins and Sanford S. Zweifach on November 21, 2011 and is headquartered in San Francisco, CA.	Corporate Officer/Principal	01.04.2012	01.05.2014
STRUCTURE THERAPEUTICS INC.	Corporate Officer/Principal	01.05.2021	-

University of California, Berkeley

Undergraduate Degree

International

Vereinigte Staaten

Operativ

Corporate Officer/Principal	5
Undergraduate Degree	1

Sektoral

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	3
SANGAMO THERAPEUTICS, INC.	Health Technology
STRUCTURE THERAPEUTICS INC.	Commercial Services
TERNS PHARMACEUTICALS, INC.	Health Technology

Private Unternehmen	2
Ascendancy Healthcare, Inc. Ascendancy Healthcare, Inc. Pharmaceuticals: MajorHealth Technology Ascendancy Healthcare, Inc. engages in the commercialization of pharmaceutical productS. It enables product entry by providing clinical, regulatory and commercial expertise and oversight along with funding. The company was founded by Arthur Joseph Higgins and Sanford S. Zweifach on November 21, 2011 and is headquartered in San Francisco, CA.	Health Technology
Adamas Pharmaceuticals LLC Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.	Health Technology

Private Unternehmen

Health Technology